Sanofi Cost Of Revenue vs Capex To Revenue Analysis

SNY Stock

USD 54.50 0.51 0.94%

Sanofi ADR financial indicator trend analysis is much more than just breaking down Sanofi ADR prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Sanofi ADR is a good investment. Please check the relationship between Sanofi ADR Cost Of Revenue and its Capex To Revenue accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sanofi ADR. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

For more information on how to buy Sanofi Stock please use our How to Invest in Sanofi ADR guide.

Cost Of Revenue vs Capex To Revenue

Cost Of Revenue vs Capex To Revenue Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Sanofi ADR Cost Of Revenue account and Capex To Revenue. At this time, the significance of the direction appears to have significant contrarian relationship.

The correlation between Sanofi ADR's Cost Of Revenue and Capex To Revenue is -0.21. Overlapping area represents the amount of variation of Cost Of Revenue that can explain the historical movement of Capex To Revenue in the same time period over historical financial statements of Sanofi ADR, assuming nothing else is changed. The correlation between historical values of Sanofi ADR's Cost Of Revenue and Capex To Revenue is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Cost Of Revenue of Sanofi ADR are associated (or correlated) with its Capex To Revenue. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Capex To Revenue has no effect on the direction of Cost Of Revenue i.e., Sanofi ADR's Cost Of Revenue and Capex To Revenue go up and down completely randomly.

Correlation Coefficient

-0.21

Relationship Direction	Negative
Relationship Strength	Insignificant

View All Relationships

Cost Of Revenue

Cost of Revenue is found on Sanofi ADR income statement and represents the costs associated with goods and services Sanofi ADR provides. Indirect cost, such as salaries, is not included. In other words, cost of revenue is the total cost incurred to obtain a sale. It is more than the traditional cost of goods sold, since it includes specific selling and marketing activities.

Capex To Revenue

The ratio of a company's capital expenditures to its total revenue, indicating how much of the revenue is used for acquiring or maintaining physical assets.

Most indicators from Sanofi ADR's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Sanofi ADR current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sanofi ADR. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

For more information on how to buy Sanofi Stock please use our How to Invest in Sanofi ADR guide.At this time, Sanofi ADR's Selling General Administrative is fairly stable compared to the past year. Sales General And Administrative To Revenue is likely to rise to 0 in 2025, despite the fact that Discontinued Operations is likely to grow to (110.3 M).

	2022	2023	2024	2025 (projected)
Gross Profit	31.7B	31.8B	36.6B	22.0B
Total Revenue	45.4B	46.0B	52.9B	31.3B

Gross Profit Total Revenue

Sanofi ADR fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Good Will	Common Stock Total Equity	Common Stock Shares Outstanding	Short Term Investments	Non Current Liabilities Total	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Short Term Debt	Intangible Assets
Total Assets		0.86	0.57	0.93	0.99	0.98	0.65	0.69	0.76	0.99	0.28	0.69	0.98	1.0	0.85	-0.17	-0.57	0.9	0.97	0.13	-0.1	0.98	0.49	0.91	0.54	0.84
Short Long Term Debt Total	0.86		0.41	0.81	0.79	0.8	0.86	0.57	0.76	0.84	0.3	0.72	0.81	0.87	0.63	-0.24	-0.35	0.9	0.84	0.11	-0.38	0.93	0.22	0.83	0.59	0.66
Other Current Liab	0.57	0.41		0.72	0.59	0.47	0.23	0.96	0.47	0.54	-0.51	0.49	0.48	0.56	0.38	-0.65	-0.05	0.3	0.64	0.1	0.16	0.52	0.86	0.58	0.18	0.57
Total Current Liabilities	0.93	0.81	0.72		0.93	0.87	0.58	0.78	0.77	0.91	0.02	0.73	0.88	0.93	0.66	-0.45	-0.33	0.72	0.97	0.16	-0.08	0.91	0.55	0.91	0.48	0.76
Total Stockholder Equity	0.99	0.79	0.59	0.93		0.97	0.56	0.7	0.76	0.98	0.25	0.69	0.97	0.99	0.85	-0.18	-0.56	0.84	0.97	0.1	-0.02	0.95	0.52	0.9	0.51	0.84
Property Plant And Equipment Net	0.98	0.8	0.47	0.87	0.97		0.61	0.6	0.7	0.98	0.4	0.62	0.99	0.97	0.9	-0.08	-0.62	0.89	0.93	0.11	-0.02	0.95	0.44	0.86	0.57	0.83
Net Debt	0.65	0.86	0.23	0.58	0.56	0.61		0.42	0.32	0.69	0.3	0.27	0.64	0.66	0.49	-0.15	-0.32	0.81	0.61	-0.01	-0.4	0.76	0.18	0.48	0.52	0.66
Accounts Payable	0.69	0.57	0.96	0.78	0.7	0.6	0.42		0.52	0.69	-0.32	0.52	0.62	0.69	0.52	-0.56	-0.23	0.48	0.74	0.0	0.0	0.66	0.86	0.64	0.29	0.68
Cash	0.76	0.76	0.47	0.77	0.76	0.7	0.32	0.52		0.68	0.16	0.99	0.68	0.77	0.55	-0.27	-0.25	0.64	0.77	0.22	-0.18	0.75	0.17	0.92	0.43	0.39
Non Current Assets Total	0.99	0.84	0.54	0.91	0.98	0.98	0.69	0.69	0.68		0.3	0.6	0.99	0.99	0.86	-0.15	-0.59	0.9	0.96	0.04	-0.08	0.97	0.51	0.85	0.54	0.89
Non Currrent Assets Other	0.28	0.3	-0.51	0.02	0.25	0.4	0.3	-0.32	0.16	0.3		0.08	0.37	0.3	0.47	0.64	-0.63	0.51	0.12	0.09	-0.27	0.32	-0.41	0.19	0.46	0.12
Cash And Short Term Investments	0.69	0.72	0.49	0.73	0.69	0.62	0.27	0.52	0.99	0.6	0.08		0.6	0.7	0.45	-0.34	-0.14	0.55	0.72	0.2	-0.19	0.68	0.15	0.88	0.4	0.31
Net Receivables	0.98	0.81	0.48	0.88	0.97	0.99	0.64	0.62	0.68	0.99	0.37	0.6		0.97	0.89	-0.09	-0.63	0.91	0.94	0.1	-0.05	0.96	0.47	0.86	0.55	0.87
Good Will	1.0	0.87	0.56	0.93	0.99	0.97	0.66	0.69	0.77	0.99	0.3	0.7	0.97		0.85	-0.16	-0.57	0.9	0.97	0.11	-0.13	0.98	0.47	0.91	0.52	0.83
Common Stock Total Equity	0.85	0.63	0.38	0.66	0.85	0.9	0.49	0.52	0.55	0.86	0.47	0.45	0.89	0.85		0.22	-0.83	0.86	0.74	0.19	-0.02	0.83	0.49	0.73	0.5	0.74
Common Stock Shares Outstanding	-0.17	-0.24	-0.65	-0.45	-0.18	-0.08	-0.15	-0.56	-0.27	-0.15	0.64	-0.34	-0.09	-0.16	0.22		-0.6	0.09	-0.35	0.23	-0.19	-0.15	-0.4	-0.23	-0.15	-0.24
Short Term Investments	-0.57	-0.35	-0.05	-0.33	-0.56	-0.62	-0.32	-0.23	-0.25	-0.59	-0.63	-0.14	-0.63	-0.57	-0.83	-0.6		-0.67	-0.41	-0.25	0.23	-0.56	-0.31	-0.44	-0.28	-0.43
Non Current Liabilities Total	0.9	0.9	0.3	0.72	0.84	0.89	0.81	0.48	0.64	0.9	0.51	0.55	0.91	0.9	0.86	0.09	-0.67		0.81	0.13	-0.3	0.95	0.27	0.78	0.54	0.76
Inventory	0.97	0.84	0.64	0.97	0.97	0.93	0.61	0.74	0.77	0.96	0.12	0.72	0.94	0.97	0.74	-0.35	-0.41	0.81		0.05	-0.07	0.95	0.52	0.9	0.46	0.82
Other Current Assets	0.13	0.11	0.1	0.16	0.1	0.11	-0.01	0.0	0.22	0.04	0.09	0.2	0.1	0.11	0.19	0.23	-0.25	0.13	0.05		-0.14	0.16	-0.03	0.38	0.0	-0.17
Other Stockholder Equity	-0.1	-0.38	0.16	-0.08	-0.02	-0.02	-0.4	0.0	-0.18	-0.08	-0.27	-0.19	-0.05	-0.13	-0.02	-0.19	0.23	-0.3	-0.07	-0.14		-0.22	0.21	-0.16	0.11	0.14
Total Liab	0.98	0.93	0.52	0.91	0.95	0.95	0.76	0.66	0.75	0.97	0.32	0.68	0.96	0.98	0.83	-0.15	-0.56	0.95	0.95	0.16	-0.22		0.43	0.9	0.55	0.82
Property Plant And Equipment Gross	0.49	0.22	0.86	0.55	0.52	0.44	0.18	0.86	0.17	0.51	-0.41	0.15	0.47	0.47	0.49	-0.4	-0.31	0.27	0.52	-0.03	0.21	0.43		0.37	0.11	0.61
Total Current Assets	0.91	0.83	0.58	0.91	0.9	0.86	0.48	0.64	0.92	0.85	0.19	0.88	0.86	0.91	0.73	-0.23	-0.44	0.78	0.9	0.38	-0.16	0.9	0.37		0.47	0.59
Short Term Debt	0.54	0.59	0.18	0.48	0.51	0.57	0.52	0.29	0.43	0.54	0.46	0.4	0.55	0.52	0.5	-0.15	-0.28	0.54	0.46	0.0	0.11	0.55	0.11	0.47		0.49
Intangible Assets	0.84	0.66	0.57	0.76	0.84	0.83	0.66	0.68	0.39	0.89	0.12	0.31	0.87	0.83	0.74	-0.24	-0.43	0.76	0.82	-0.17	0.14	0.82	0.61	0.59	0.49

Click cells to compare fundamentals

Sanofi ADR Account Relationship Matchups

Sanofi ADR fundamental ratios Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	114.4B	120.2B	126.7B	126.5B	145.4B	88.7B
Short Long Term Debt Total	23.7B	22.4B	21.2B	18.4B	21.2B	13.7B
Other Current Liab	10.1B	11.0B	11.9B	13.9B	16.0B	16.8B
Total Current Liabilities	19.2B	21.3B	24.0B	24.2B	27.8B	14.4B
Total Stockholder Equity	63.1B	68.7B	74.8B	74.0B	85.1B	50.5B
Property Plant And Equipment Net	10.6B	12.0B	11.7B	11.8B	13.6B	8.5B
Net Debt	9.8B	12.3B	8.5B	9.7B	11.2B	7.6B
Accounts Payable	5.3B	6.2B	6.8B	7.3B	8.4B	8.8B
Cash	13.9B	10.1B	12.7B	8.7B	10.0B	6.2B
Non Current Assets Total	80.7B	89.7B	92.7B	95.8B	110.2B	66.5B
Non Currrent Assets Other	600M	731M	882M	588M	529.2M	502.7M
Cash And Short Term Investments	13.9B	10.1B	12.7B	8.7B	10.0B	6.9B
Net Receivables	10.0B	9.8B	10.7B	11.0B	12.7B	7.7B
Good Will	44.4B	48.1B	49.9B	49.4B	56.8B	33.9B
Common Stock Shares Outstanding	1.3B	1.3B	1.3B	1.3B	1.1B	1.7B
Liabilities And Stockholders Equity	114.4B	120.2B	126.7B	126.5B	145.4B	88.7B
Non Current Liabilities Total	31.9B	29.9B	27.6B	27.9B	32.1B	23.6B
Inventory	8.4B	8.7B	9.0B	9.7B	11.1B	5.6B
Other Current Assets	1.5B	2.0B	1.6B	1.2B	1.4B	1.8B
Other Stockholder Equity	(343M)	(407M)	(581M)	(871M)	(783.9M)	(823.1M)
Total Liab	51.2B	51.2B	51.6B	52.1B	59.9B	38.0B
Property Plant And Equipment Gross	10.6B	12.0B	11.7B	27.4B	31.6B	33.1B
Total Current Assets	33.7B	30.6B	34.0B	30.7B	35.3B	22.2B
Accumulated Other Comprehensive Income	782M	3.5B	6.1B	4.9B	5.6B	5.3B
Short Term Debt	3.0B	3.5B	4.5B	2.3B	2.7B	2.9B
Intangible Assets	18.3B	21.4B	21.6B	24.3B	28.0B	18.2B
Common Stock	2.5B	2.5B	2.5B	2.5B	2.9B	2.6B
Other Liab	12.1B	11.4B	11.0B	10.8B	12.5B	11.9B
Current Deferred Revenue	252M	319M	264M	597M	686.6M	652.2M
Retained Earnings	60.1B	63.0B	66.7B	67.5B	77.6B	73.7B
Other Assets	8.8B	11.4B	13.5B	12.9B	14.8B	9.8B
Long Term Debt	19.7B	17.1B	14.9B	14.3B	16.5B	12.7B
Property Plant Equipment	11.0B	10.6B	12.0B	11.7B	13.4B	10.5B
Deferred Long Term Liab	2.3B	6.1B	7.7B	6.2B	7.2B	4.0B
Long Term Investments	7.1B	8.0B	9.2B	2.7B	3.1B	2.9B
Short Long Term Debt	2.8B	3.2B	4.2B	2.0B	1.8B	3.2B
Net Tangible Assets	177M	6.3B	6.9B	9.5B	8.5B	4.6B

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

CSX	CSX Corporation
ETON	Eton Pharmaceuticals
ALLT	Allot Communications

Additional Tools for Sanofi Stock Analysis

When running Sanofi ADR's price analysis, check to measure Sanofi ADR's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sanofi ADR is operating at the current time. Most of Sanofi ADR's value examination focuses on studying past and present price action to predict the probability of Sanofi ADR's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sanofi ADR's price. Additionally, you may evaluate how the addition of Sanofi ADR to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Sanofi Cost Of Revenue vs Capex To Revenue Analysis

Cost Of Revenue vs Capex To Revenue

Cost Of Revenue vs Capex To Revenue Correlation Analysis

Correlation Coefficient

Cost Of Revenue

Capex To Revenue

Sanofi ADR fundamental ratios Correlations

Sanofi ADR Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Sanofi ADR fundamental ratios Accounts

Also Currently Popular

Additional Tools for Sanofi Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Good Will	+ 1.0	Total Assets
Total Stockholder Equity	+ 0.99	Total Assets
Non Current Assets Total	+ 0.99	Total Assets
Good Will	+ 0.99	Total Stockholder Equity
Net Receivables	+ 0.99	Property Plant And Equipment Net
Cash And Short Term Investments	+ 0.99	Cash

Short Term Investments	- 0.83	Common Stock Total Equity
Non Current Liabilities Total	- 0.67	Short Term Investments
Common Stock Shares Outstanding	- 0.65	Other Current Liab
Short Term Investments	- 0.63	Net Receivables
Short Term Investments	- 0.63	Non Currrent Assets Other
Short Term Investments	- 0.62	Property Plant And Equipment Net